News

The acquisition will expand Apria’s service offering by creating a nationwide home infusion provider. The transaction also enables Apria to immediately enter the large and rapidly-growing specialty pharmaceutical

ImClone and Bristol-Myers Squibb have signed an agreement with German pharma major Merck for the co-development and co-commercialization of Erbitux (cetuximab) in Japan. Under the terms of the

Approximately 40 sites will participate in each of these two studies, which are being conducted by Wyeth. Each trial is expected to enroll approximately 120 patients who are

Biopure expects to move on several fronts, emphasizing clinical development in Europe. The company has also identified the next step in its ischemia clinical program and has proposed

The Type 1 Diabetes Genetics Consortium (T1DGC) will attempt to identify genes that influence an individual’s risk for developing type 1 diabetes. Principal Investigator Stephen Rich, from the

In consideration for the selective androgen receptor modulator (SARM) program license, Pharmacopeia will apply a portion of its medicinal chemistry resources to an unrelated Bristol-Myers Squibb discovery program

A statistically significant reduction of urinary 5-hydroxyindoleacetic acid, a metabolite of serotonin and biomarker for serotonin production, was observed in subjects who received the highest dose tested, 2,000mg

Corgenix is part of a collaborative group that has developed and patented new recombinant proteins for Lassa virus. The clinical test kits were developed under a $3.8 million

The re-analysis demonstrates that vaginal progesterone is associated with a significantly lower rate of miscarriage than IM progesterone. The data was presented by Dr Paul Zarutskie, Zarutskie Fertility